Skip to content


Singulair (montelukast) is a small molecule pharmaceutical. Montelukast was first approved as Singulair on 1998-02-20. It is used to treat allergic rhinitis perennial and asthma in the USA. The pharmaceutical is active against cysteinyl leukotriene receptor 1. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and cytochrome P450 2C8. Singulair's patent is valid until 2022-10-24 (FDA).
Trade Name Singulair
Common Name Montelukast
Indication allergic rhinitis perennial, asthma
Drug Class Antiasthmatics/antiallergics: leukotriene receptor antagonists
Get full access now